Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.
复制标题
DOI：
10.3390/ijms18112291
复制
发表时间：
2017-10-31
影响因子：
5.6
通讯作者：
Heidegger I
中科院分区：
文献类型：
--
作者：
Pircher A;Wolf D;Heidenreich A;Hilbe W;Pichler R;Heidegger I
近年来，转移性癌症患者的治疗策略取得了相当大的进展。特别是在肾细胞癌（RCC）和晚期非小细胞肺癌（NSCLC）中，免疫激活和抗血管生成（AA）药物（即检查点抗体和血管内皮生长因子（VEGF）/VEGF受体（VEGFR）靶向化合物，分别）已成功开发。由于免疫效应细胞必须进入肿瘤，因此人们很容易推测免疫疗法与 AA 治疗相结合可能会产生协同效应。在这篇简短的综述中，我们探讨了这种新型治疗方案对晚期 RCC 或 NSCLC 患者的理论背景和治疗潜力。我们讨论了越来越多的证据表明促血管生成因子负向调节 T 细胞介导的免疫反应，并检查了在临床实践中测试免疫激活和 AA 联合治疗概念的临床前证据。还将特别关注联合治疗引起的潜在新型治疗相关不良事件。
In recent years, considerable advances concerning therapeutic strategies in patients with metastatic cancer have been achieved. Particularly in renal cell cancer (RCC) and advanced stage non-small cell lung cancer (NSCLC), immune-activating and antiangiogenic (AA) drugs (i.e., checkpoint antibodies and vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR) targeting compounds, respectively) have been successfully developed. As immune-effector cells have to enter the tumor, it is tempting to speculate that the combination of immunotherapy with AA treatment may induce synergistic effects. In this short review, we explore the theoretical background and the therapeutic potential of this novel treatment option for patients with advanced RCC or NSCLC. We discuss the growing body of evidence that pro-angiogenic factors negatively modulate the T-cell-mediated immune response and examine the preclinical evidence for testing combined immune-activating and AA therapy concepts in clinical practice. Particular attention will also be paid to potential novel treatment-related adverse events induced by combination treatment.
登录
查看更多内容
影响因子：
17.1
作者：
Allen E;Jabouille A;Rivera LB;Lodewijckx I;Missiaen R;Steri V;Feyen K;Tawney J;Hanahan D;Michael IP;Bergers G
通讯作者：
Bergers G
影响因子：
6.2
作者：
Cindolo, L;Patard, JJ;Gallo, C
通讯作者：
Gallo, C
影响因子：
7.3
作者：
Hendry SA;Farnsworth RH;Solomon B;Achen MG;Stacker SA;Fox SB
通讯作者：
Fox SB
影响因子：
4.8
作者：
Dirkx, Anita E. M.;Egbrink, Mirjam G. A. oude;Griffioen, Arjan W.
通讯作者：
Griffioen, Arjan W.
影响因子：
11.5
作者：
Ko, Jennifer S.;Zea, Arnold H.;Finke, James H.
通讯作者：
Finke, James H.